AIM ImmunoTech Inc. Common Stock (AIM)
$0.12
0.00 (0.00%)
AIM Stock Quote Delayed 30 Minutes
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
Another day of investing awaits for traders as we start it off with a breakdown of the biggest pre-market stock movers for Monday!
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Unlock Louis Navellier's
? Stock Report – FREE:
Is ? a BUY?
Powered by Portfolio Grader
A
B
C
D
F
?
Unlock Louis Navellier's
? Stock Report to Find Out – FREE:
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Investing legend Louis Navellier rates ? a "?." Unlock his ? Stock Analysis to find out why – FREE:
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Fundamental Grade
Quantitative Grade
- Sales Growth ?
- Operating Margin Growth ?
- Earnings Growth ?
- Earnings Momentum ?
- Earnings Surprises ?
- Analyst Earnings Revisions ?
- Cash Flow ?
- Return on Equity ?
Previous Close
-
Market Cap
498,119
PE Ratio
0.21
EPS
0.6
Volume (Avg. Vol.)
2
Day's Range
-
52-Week Range
$0.11 - $0.62
Dividend & Yield
N/A (N/A)
AIM Stock Predictions, Articles, and AIM ImmunoTech Inc. Common Stock News
Aim ImmunoTech News: Why AIM Stock Is Shooting 22% Higher Today
Aim ImmunoTech (AIM) is in the news Tuesday after positive results from an Early Access Program (EAP) sent AIM stock soaring higher.
AIM ImmunoTech Seduces With Coronavirus Treatment Potential
One of the things that's been keeping interest in AIM somewhat strong since that March plunge is that no company has pinned down an effective coronavirus treatment or vaccine. It's not a stretch to say some ambitious, risk-tolerant investors may be looking at AIM through the lens of the “door's open, why not AIM?”
2 Pros, 2 Cons for Buying AIM ImmunoTech
AIM stock has entered Wall Street’s consciousness due to the underlying biotech firm’s potential coronavirus treatment. However, will this be enough to keep shares moving higher?
Coronavirus Research Is the Key for AIM ImmunoTech Stock
One big breakthrough moment in coronavirus research could bring wealth to AIM ImmunoTech. It could also bring big gains to AIM stock.
AIM Stock Is a Moonshot That Lacks the Fuel
Though AIM stock is relevant on paper, with competition raging in the race for a coronavirus treatment, along with AIM ImmunoTech's checkered past, this is a very speculative gamble.
Don’t Pull the Trigger on AIM ImmunoTech Stock
If it sounds too good to be true, it probably is. And that's likely the case when you look deeper into what's going on with AIM ImmunoTech stock.
AIM Stock: You’ve Got a Better Shot of Getting Rich Buying a Lottery Ticket
AIM ImmunoTech reported its 2019 results on March 31. Despite the coronavirus push, AIM stock headed lower on the news.
Read the Label Before Buying AIM Stock
One of the few sectors that have enjoyed upside is the pharmaceutical industry. In particular, AIM stock has jumped on a possible Covid-19 treatment. Nevertheless, you want to look carefully at the label before jumping aboard.
In the Coronavirus Vaccine Race, AIM Stock Isn’t a Likely Winner
AIM stock was a big winner on hopes it could join the response to the coronavirus. But its history suggests those hopes are too optimistic.
GT Biopharma News: GTBP Stock Spikes 26% on Coronavirus Treatment Hopes
GT Biopharma (GTBP) news for Tuesday about it working on a possible treatment for the coronavirus from China has GTBP stock heading higher.
AIM ImmunoTech News: AIM Stock Skyrockets 208% on Hopes for COVID-19 Treatment
AIM ImmunoTech (AIM) news for Monday concerning a possible treatment for the coronavirus from China has AIM stock rocketing higher.
